"Sanofi-aventis now expects business EPS1 growth for 2010 to be between 0% and 2% versus 20094 business EPS, at constant exchange rates and barring major unforeseen adverse events. This guidance takes into account generic competition for Ambien CR® in the U.S., possible entry of generics of Taxotere® in the U.S. and the E.U. and further erosion of Lovenox® sales in the U.S."
As I read the statement, on its face, SNY expects "further erosion of Lovenox sales" ...
Market Data 
Markets 
AI
